BioMed X, an external innovation hub for pharma, has launched a new collaborative research project with AbbVie, hosted at the BioMed X Institute in New Haven, Connecticut.

The topic of the new research project in the field of neuroscience is the development of “Circuit-Based Model Systems of Anhedonia.” Anhedonia, the diminished ability to experience pleasure, remains one of the most challenging and poorly treated symptoms of depression, as well as several other psychiatric conditions.

The focus of this collaboration will be on the identification of specific mechanisms that underpin this debilitating symptom, using patient-derived data to validate mechanistic insights wherever possible.

With their global call for applications, BioMed X and AbbVie invite researchers world-wide to submit proposals for innovative research projects aimed at uncovering the entangled microcircuits and molecular targets disrupted in anhedonia. Proposals that integrate interdisciplinary approaches, including neurobiology, molecular biology, AI/machine learning, and clinical data, will be prioritized.

Interested researchers are invited to submit their project proposals via the BioMed X Career Space by January 18, 2026.